These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37558921)

  • 21. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
    Müller T; Riederer P; Grünblatt E
    J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
    Meiring L; Petzer JP; Legoabe LJ; Petzer A
    Bioorg Med Chem Lett; 2022 Jul; 67():128746. PubMed ID: 35447344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inhibitory monoamine oxidases of the new generation].
    Nowakowska E; Chodera A
    Pol Merkur Lekarski; 1997 Jul; 3(13):1-4. PubMed ID: 9432289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 26. Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development.
    Aljanabi R; Alsous L; Sabbah DA; Gul HI; Gul M; Bardaweel SK
    Molecules; 2021 Oct; 26(19):. PubMed ID: 34641563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoamine oxidase inhibitors. A perspective on their use in the elderly.
    Volz HP; Gleiter CH
    Drugs Aging; 1998 Nov; 13(5):341-55. PubMed ID: 9829163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The inhibition of monoamine oxidase by 2H-1,4-benzothiazin-3(4H)-ones.
    Hitge R; Petzer JP; Petzer A
    Bioorg Med Chem Lett; 2022 Dec; 77():129038. PubMed ID: 36307034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson's Disease - An Update.
    Chew ZX; Lim CL; Ng KY; Chye SM; Ling APK; Koh RY
    CNS Neurol Disord Drug Targets; 2023; 22(3):329-352. PubMed ID: 34970960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoamine oxidase B inhibitors for early Parkinson's disease.
    Macleod AD; Counsell CE; Ives N; Stowe R
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived
    Lee HW; Choi H; Nam SJ; Fenical W; Kim H
    J Microbiol Biotechnol; 2017 Apr; 27(4):785-790. PubMed ID: 28068665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoamine Oxidases.
    Edmondson DE; Binda C
    Subcell Biochem; 2018; 87():117-139. PubMed ID: 29464559
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Boulaamane Y; Ibrahim MAA; Britel MR; Maurady A
    J Integr Bioinform; 2022 Dec; 19(4):. PubMed ID: 36112816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
    Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
    Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
    JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.
    Finberg JP
    Pharmacol Ther; 2014 Aug; 143(2):133-52. PubMed ID: 24607445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
    Dezsi L; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent Selective Inhibition of Monoamine Oxidase A by Alternariol Monomethyl Ether Isolated from
    Lee HW; Kim YJ; Nam SJ; Kim H
    J Microbiol Biotechnol; 2017 Feb; 27(2):316-320. PubMed ID: 27840401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C6- and C7-Substituted 3,4-dihydro-2(1H)-quinolinones as Inhibitors of Monoamine Oxidase.
    Meiring L; Petzer JP; Petzer A
    Drug Res (Stuttg); 2017 Mar; 67(3):170-178. PubMed ID: 27926950
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.